DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

CI·The Cigna Group

$.
+. (+.%)
Pre-Market
High
$284.60
Open
$280.97
Market Cap
75.73B
52W High
$315.47
Low
$280.97
P. Close
$284.00
P/E
12.04
52W Low
$239.51
Fwd P/E
39.19
DailyIQ Est.
$352.72
Technical Score (1D)
55
BUY
News Sentiment
70
BULLISH
Argus Research has lifted its target price for CI to $334, citing an improved earnings outlook and stronger margin expansion that reflect confidence in the company’s strategic initiatives and growing demand for its products. Bernstein has also upgraded CI to an Outperform rating and raised its target to $381, highlighting the insurer’s ability to manage medical costs and the strong performance of its Evernorth division, which could drive earnings growth through 2030. The dual upgrades suggest a consensus that CI’s earnings trajectory is improving, which could support a more favorable valuation in the near term. Traders should keep an eye on CI’s upcoming Q2 earnings release later this month, as the guidance and actual results will be the first concrete test of the upgraded outlook. In addition, CI’s removal from the Russell 1000 Growth and Russell 3000 Growth indices could trigger rebalancing by passive funds, potentially affecting liquidity and short‑term demand. The company’s $100 million investment in Pharmacy Forward, an AI‑driven specialty pharmacy platform, signals a strategic shift toward digital pharmacy services that could reduce costs and enhance member care, but integration risk remains. CI’s broader expansion beyond traditional health insurance—through AI analytics, specialty pharmacy, and direct healthcare services—aims to capture higher‑margin opportunities and diversify revenue, which may influence operating margins over the next few quarters. Watch for any updates to CI’s long‑term outlook, regulatory developments in the health‑insurance sector, and the performance of the Pharmacy Forward initiative as these factors could materially affect the company’s valuation. Finally, monitor how passive fund rebalancing and the timing of the Q2 earnings call may create short‑term volatility in the next 1–10 trading days.
Earnings Summary
The Cigna Group, a U.S.‑based health insurer, operates through Evernorth Health Services and Cigna Healthcare, delivering medical, dental, and behavioral coverage to individuals, seniors, and employers while also managing pharmacy benefits and care delivery solutions; it sits within the broader healthcare plans sector. In the most recent two quarters, Cigna’s Q1 2026 revenue rose 4.5% year‑over‑year to $68.5 billion, a modest increase compared with the 10% jump seen in Q4 2025, while EPS climbed 15% to $7.79, beating the $7.61 consensus; Q2 2026 EPS remains pending, though revenue estimates of $72.5 billion suggest continued top‑line momentum. Over the preceding two quarters, Q3 2025 and Q4 2025, the company posted revenue growth of 10% and 10% respectively and EPS gains of 15% and 22%, indicating a pattern of accelerating earnings growth even as revenue expansion has begun to moderate. Historically, Cigna has delivered consistent YoY revenue growth—10% in Q4 2025 and 4.5% in Q1 2026—while EPS has outpaced revenue, with a 22% rise in Q4 2025 and 15% in Q1 2026, and the firm has beaten analyst estimates in five of the last six quarters, underscoring disciplined cost control and robust Evernorth performance. Recent news highlights Bernstein’s upgrade to an Outperform rating and a $381 price target, citing stronger cost‑control initiatives and Evernorth’s growth, while Argus Research’s $315 target and a $100 million investment in Pharmacy Forward AI signal confidence in operational efficiencies and specialty pharmacy margins; these developments reinforce expectations of continued earnings resilience. Investors should watch for the Q2 2026 earnings release to confirm EPS trajectory, monitor guidance for any shifts in cost‑control or Evernorth margin dynamics, and track the rollout of Pharmacy Forward AI, as well as any regulatory changes that could impact reimbursement rates or medical loss ratios, all of which will be pivotal in shaping the next quarter’s performance.

EPS

EstBeatMiss
$6.09$6.65$7.21$7.78$8.34Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$7.60 - -
Q1'26$7.61$7.79+2.4%
Q4'25$7.50$8.08+7.8%
Q3'25$7.64$7.83+2.5%
Q2'25$7.15$7.20+0.6%
Q1'25$6.35$6.74+6.2%

Revenue

EstBeatMiss
$64.4B$66.7B$69.0B$71.3B$73.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$72.5B - -
Q1'26$66.2B$68.5B+3.5%
Q4'25$66.4B$72.5B+9.2%
Q3'25 - $69.7B -
Q2'25 - $67.2B -
Q1'25 - $65.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CI Stock Snapshot

CI is currently trading at $284.60, giving The Cigna Group a market cap of 75.73B and a P/E ratio of 12.0. Today's range spans $280.97–$284.60, with shares opening at $280.97 and moving up $0.60 (0.2%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 70/100.

Over the past year CI has traded between $239.51 and $315.47 - the current price is +18.8% off the 52-week low and -9.8% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $340.92 (range $290.00–$400.00), implying upside of +19.8%.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, CI (55/100, HOLD, price $284.60, in the middle of its 52-week range) is waiting for that resolution. Sentiment: bullish at 70/100. The current P/E ratio stands at 12.0. With 75.73B in market cap, the 52-week range of $239.51–$315.47 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

Portfolio construction in Healthcare often uses large-cap names like CI as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 55/100 (HOLD) at $284.60 (in the middle of its 52-week range) and bullish sentiment (70/100) frame the position as a catalyst play within the $239.51–$315.47 annual range rather than a directional bet.